Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Paladin Labs has expanded its current exclusive Canadian distribution agreement with Shire Human Genetic Therapies to include Elaprase for Hunter syndrome in addition to Replagal for Fabry disease.
Subscribe to our email newsletter
Health Canada recently granted Shire HGT regulatory approval for Elaprase, indicated for enzyme replacement therapy in patients with Hunter syndrome.
Hunter syndrome is an X-linked recessive disorder caused by a deficiency or absence of iduronate-2-sulfatase (I2S). Its absence results in a harmful accumulation of cellular waste products in cells throughout the body. Hunter syndrome is one of a group of extremely rare hereditary metabolic diseases known collectively as lysosomal storage disorders.
Elaprase is designed to treat the underlying cause of Hunter syndrome by replacing I2S. The drug is a purified form of human I2S produced by recombinant DNA technology using a human cell line.
“Hunter syndrome is a devastating condition and we are pleased to expand our partnership with Shire,” said Jonathan Ross Goodman, president and CEO of Paladin. “Elaprase is now available in Canada.”